Profound Medical (PROF) outlines upcoming investor events in new filing

Rhea-AI Filing Summary

Profound Medical Corp. furnished a current report to let investors know it has issued a press release announcing upcoming investor events. The company attached this press release as Exhibit 99.1 so readers can access the full details of those events.

The company specifically states that the information about these investor events, including the exhibit, is being provided under Regulation FD and is considered "furnished" rather than "filed" under U.S. securities laws. This means it is not subject to certain liability provisions and is not automatically incorporated into other SEC filings.

False000162880800016288082026-01-272026-01-27iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  January 27, 2026

_______________________________

PROFOUND MEDICAL CORP.

(Exact name of registrant as specified in its charter)

_______________________________

Ontario, Canada	001-39032	Not Applicable
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

2400 Skymark Avenue, Unit 6

Mississauga, Ontario, Canada L4W 5K5

(Address of Principal Executive Offices) (Zip Code)

Registrant's Telephone Number, Including Area Code: 647-476-1350

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Shares	PROF	The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On January 27, 2026, Profound Medical Corp. (the “Company”) issued a press release announcing upcoming investor events. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or the Exchange Act, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, or the Securities Act. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the U.S. Securities Exchange Commission, or the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release, dated January 27, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PROFOUND MEDICAL CORP.
Date: January 27, 2026	By:	/s/ Rashed Dewan
		Rashed Dewan
		Chief Financial Officer

FAQ

What did Profound Medical Corp. (PROF) disclose in this 8-K filing?

Profound Medical Corp. disclosed that it issued a press release announcing upcoming investor events. The release is attached as Exhibit 99.1, providing detailed information about those events for shareholders and market participants.

How is the press release about investor events treated under securities laws?

The press release and related information are treated as "furnished" under Regulation FD, not "filed". This means they are not subject to certain liability provisions of the Exchange Act and Securities Act that apply to filed documents.

Is the Profound Medical (PROF) investor events press release incorporated into other SEC filings?

No. The company states that the information in Item 7.01 and Exhibit 99.1 is not incorporated by reference into any other SEC filing, regardless of general incorporation language used elsewhere.

Which exhibit in the Profound Medical 8-K contains details on the investor events?

Exhibit 99.1 contains the press release dated January 27, 2026, announcing the upcoming investor events. Readers must review this exhibit to see the specific timing, format, and nature of the events.

Why did Profound Medical use Item 7.01 for this investor events announcement?

Item 7.01 is used for Regulation FD disclosures to ensure fair and simultaneous access to material information. By using this item, Profound Medical aims to provide broad, non-selective disclosure about its upcoming investor events.